Quarterly Result4 Aug 2026, 02:11 pm
Morepen Labs Reports Record Q1 FY27 Revenue and Earnings
AI Summary
Morepen Laboratories Ltd. announced its highest-ever quarterly revenue and earnings for Q1 FY27, with revenue reaching ₹575.31 Cr, a 34% year-on-year increase. EBITDA surged by 207% to ₹87.72 Cr, and Profit After Tax (PAT) grew by 394% to ₹56.35 Cr. The company's CDMO mandate, valued at ₹825 Cr, entered full-scale commercialization, with ₹58 Cr in dispatches completed during the quarter. API business grew 31% with exports up 42%, and Medical Devices saw 19% growth. The company also maintained a strong regulatory record with four consecutive USFDA inspections yielding Nil Form 483 observations.
Key Highlights
- Record Q1 FY27 revenue of ₹575.31 Cr, up 34% YoY.
- EBITDA increased 207% to ₹87.72 Cr; PAT up 394% to ₹56.35 Cr.
- ₹825 Cr CDMO mandate enters full commercialization phase.
- API exports grew 42%, Medical Devices up 19%.
- Fourth consecutive USFDA inspection with Nil Form 483 observations.
Price Impact
More from MOREPENLAB